戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  recently have raised several monoclonal IgG anti-ganglioside antibodies.
2 mice that received systemically administered anti-ganglioside antibodies.
3 s a postinfectious autoimmune neuropathy and anti-ganglioside antibodies (Abs) are strongly associate
4                                              Anti-ganglioside antibodies (Abs) are strongly associate
5  GBS, and in particular its association with anti-ganglioside antibodies and a primary axonal neuropa
6             To examine fine specificities of anti-ganglioside antibodies and develop a more robust pl
7 nstrate first, that both GBS sera containing anti-ganglioside antibodies and monoclonal anti-ganglios
8 ediated injury over this time scale and that anti-ganglioside antibodies and the cholera toxin B subu
9  tissues contribute to target recognition by anti-ganglioside antibodies and this observation provide
10 major unexpected pathway by which pathogenic anti-ganglioside antibodies, and potentially other gangl
11 to examine binding specificities of lectins, anti-ganglioside antibodies, and serum antibodies of GBS
12 eview those studies, which clearly show that anti-ganglioside antibodies are capable of binding to NM
13                                              Anti-ganglioside antibodies are thought to play a key ro
14  In axonal forms of Guillain-Barre syndrome, anti-ganglioside antibodies bind gangliosides on nerve s
15  investigated whether endocytic clearance of anti-ganglioside antibodies by nerve terminals might als
16 injury are not completely resolved: (i) some anti-ganglioside antibodies can cross-react with glycopr
17                     These data indicate that anti-ganglioside antibodies can diffuse into a desheathe
18 g anti-ganglioside antibodies and monoclonal anti-ganglioside antibodies cause neuronal cell lysis by
19 sive transfer with systemically administered anti-ganglioside antibodies did not cause nerve fiber de
20                         Although lectins and anti-ganglioside antibodies did not differentiate the ga
21                                              Anti-ganglioside antibodies (e.g., anti-GM(1)) are assoc
22                    Our findings suggest that anti-ganglioside antibody fine specificity as well as di
23 ransmitter recycling, are able to endocytose anti-ganglioside antibodies from the cell surface so rap
24 cluding our own, have studied the effects of anti-ganglioside antibodies in ex vivo and in vivo exper
25                         However, the role of anti-ganglioside antibodies in GBS continues to be debat
26  pathological evidence to support a role for anti-ganglioside antibodies in mediating nerve terminal
27 n and by systemic administration of purified anti-ganglioside antibodies in mice.
28 ally be used for screening of (i) pathogenic anti-ganglioside antibodies in patients with immune-medi
29           Remarkably, systemically delivered anti-ganglioside antibody in mice was so avidly cleared
30 ues, we developed and characterized a simple anti-ganglioside antibody-mediated cytotoxicity assay.
31 brane pool appears to be more susceptible to anti-ganglioside antibody-mediated injury than the GM1 p
32         However, two basic issues related to anti-ganglioside antibody-mediated neural injury are not
33 d (ii) new/experimental therapies to prevent anti-ganglioside antibody-mediated neural injury.
34 lysing electrophysiologically the effects of anti-ganglioside antibodies on nerve function, possibly
35 from human and animal studies indicates that anti-ganglioside antibodies play a primary neuropathogen
36 ization with a melanoma cell vaccine induced anti-ganglioside antibody responses in melanoma patients
37 s implanted with an intraperitoneal clone of anti-ganglioside antibody-secreting hybridoma developed
38 rch into clinical associations of individual anti-ganglioside antibody specificities has been perform
39 inals of neuromuscular junctions, from where anti-ganglioside antibody was retrogradely transported t
40 in 81% of AMAN and 50% of AIDP patients, and anti-ganglioside antibodies were common in both Campylob
41                  The typical AMAN-associated anti-ganglioside antibodies were rarely present.
42 e immunostained to differing levels with the anti-ganglioside antibodies, whereas neural cells from m